• Explore /
  • Poster
  • / Updated results of a phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).

Updated results of a phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).

Abstract Poster

Authors

null

Ru Jia

Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital, Beijing, China

Ru Jia , Hai-Yan Si , Zhi-Kuan Wang , Guo-Chao Deng , Nan Zhang , Fang-Fang Liu , Yue Shi , Yao-Yue Zhang , Yu-Shan Jia , Yanrong Wang , Meng-Jiao Fan , Meng-Meng Miao , Bei Zhang , Shuang Tong , Guang-Hai Dai

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05218889

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 671)

DOI

10.1200/JCO.2024.42.3_suppl.671

Abstract #

671

Poster Bd #

L20

Abstract Disclosures

Similar Posters

First Author: Guang-Hai Dai

First Author: Dong-Sheng Zhang

First Author: Shao Zhimin

First Author: Philippa Corrie